Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years

Vaccine

Volumn 26, Issue 1, 2007, Pages 32-40

  Schmidt Ott, Ruprecht ^a   Schwarz, Tino ^b   Haase, Rainer ^c   Sander, Helga ^d   Walther, Uta ^c   Fourneau, Marc ^e   Htun Myint, Latt ^e   Sänger, Roland ^e   Schuster, Volker ^f  

^a GLAXOSMITHKLINE   (Germany)

^b Stiftung Juliusspital   (Germany)

^c Kinderzentrum Dresden Friedrichstadt ^*  (Germany)

^d ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Children; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; INFLUSPLIT SSW; TRIVALENT INACTIVE INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANALYTIC METHOD; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FEVER; HEMAGGLUTINATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; MALE; MYALGIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWELLING; VACCINATION; VIRUS STRAIN;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; VACCINES, INACTIVATED;

EID: 36749040950     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.049     Document Type: Article

References (42)

1. Heikkinen T., Booy R., Campins M., Finn A., Olcen P., Peltola H., et al. Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatr 165 4 (2006) 223-228
2. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 355 1 (2006) 31-40
3. Glezen W.P., and Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 298 11 (1978) 587-592
4. Hurwitz E.S., Haber M., Chang A., Shope T., Teo S.T., Giesick J.S., et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 182 4 (2000) 1218-1221
5. Monto A.S., and Sullivan K.M. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 110 1 (1993) 145-160
6. Glezen W.P. Morbidity associated with the major respiratory viruses. Pediatr Ann 19 9 (1990) 535-536 538, 540, passim
7. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342 4 (2000) 232-239
8. Neuzil K.M., and Edwards K.M. Influenza vaccines in children. Semin Pediatr Infect Dis 13 3 (2002) 174-181
9. Ghendon Y.Z., Kaira A.N., and Elshina G.A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134 1 (2006) 71-78
10. Jordan R., Connock M., Albon E., Fry-Smith A., Olowokure B., Hawker J., et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 24 8 (2006) 1047-1062
11. Monto A.S., Davenport F.M., Napier J.A., and Francis Jr. T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children. J Infect Dis 122 1 (1970) 16-25
12. Reichert T.A., Sugaya N., Fedson D.S., Glezen W.P., Simonsen L., and Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344 12 (2001) 889-896
13. Statement on Influenza Vaccination for the 2006-2007 Season. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2006; 32 (ACS-7):1-27.
14. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., and Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-10 (2006) 1-42
15. Ruben F.L. Influenza: getting our attention. Clin Infect Dis 40 11 (2005) 1697-1698
16. Allison M.A., Daley M.F., Crane L.A., Barrow J., Beaty B.L., Allred N., et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 149 6 (2006) 755-762
17. Clements D.A., Langdon L., Bland C., and Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 149 10 (1995) 1113-1117
18. Heikkinen T., Ruuskanen O., Waris M., Ziegler T., Arola M., and Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 145 4 (1991) 445-448
19. Hoberman A., Greenberg D.P., Paradise J.L., Rockette H.E., Lave J.R., Kearney D.H., et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 290 12 (2003) 1608-1616
20. Neuzil K.M., Dupont W.D., Wright P.F., and Edwards K.M. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20 8 (2001) 733-740
21. Ritzwoller D.P., Bridges C.B., Shetterly S., Yamasaki K., Kolczak M., and France E.K. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 116 1 (2005) 153-159
22. Negri E., Colombo C., Giordano L., Groth N., Apolone G., and La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 23 22 (2005) 2851-2861
23. Jefferson T., Smith S., Demicheli V., Harnden A., Rivetti A., and Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365 9461 (2005) 773-780
24. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338 20 (1998) 1405-1412
25. Hehme N.W., Kuenzel W., Petschke F., Türk G., Raderecht C., and Van Hoeke C. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 22 (2002) 751-769
26. Neuzil K.M., Jackson L.A., Nelson J., Klimov A., Cox N., Bridges C.B., et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194 8 (2006) 1032-1039
27. Piedra P., Piedra P.A., and Glezen W.P. Influenza in children: epidemiology, immunity, and vaccines. Semin Paediatr Infect Dis 2 (1991) 140-146
28. Wright P.F., Thompson J., Vaughn W.K., Folland D.S., Sell S.H., and Karzon D.T. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 136 Suppl. (1977) S731-S741
29. Wright P.F., Cherry J.D., Foy H.M., Glezen W.P., Hall C.B., McIntosh K., et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children-a multicentered evaluation of dosage and safety. Rev Infect Dis 5 4 (1983) 758-764
30. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epi Bull 2006; 30:235-254.
31. EU recommendations for the influenza vaccine composition for the season 2005/2006. EMEA/CPMP/BWP/1104/04.
32. Note For Guidance On Harmonization Of Requirements For Influenza Vaccines. CPMP/BWP/214/96.
33. Rose G.W., and Cooper C.L. Fluarix, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 6 3 (2006) 301-310
34. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23 4 (2004) 300-306
35. Van Hoecke C., Raue W., Kunzel W., and Engelmann H. Immunogenicity and safety of influenza vaccination in 3- to 6-year-old children with a two dose immunisation schedule. Eur J Pediatr 155 4 (1996) 346-347
36. Arbeitsgemeinschaft Influenza. Saisonabschlussberichte 1991-2005. http://www.influenza.rki.de/agi, Accessed August 10, 2007.
37. Schweiger B. Molecular characterization of human influenza viruses-a look back on the last 10 years. Berl Munch Tierarztl Wochenschr 119 3/4 (2006) 167-178
38. http://www.eiss.org/index.cgi, Accessed August 10, 2007.
39. Khan A.S., Polezhaev F., Vasiljeva R., Drinevsky V., Buffington J., Gary H., et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian school children. J Infect Dis 173 2 (1996) 453-456
40. Gruber W.C., Taber L.H., Glezen W.P., Clover R.D., Abell T.D., Demmler R.W., et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 144 5 (1990) 595-600
41. Lina B., Fletcher M.A., Valette M., Saliou P., and Aymard M. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in children, adults and the elderly. Biologicals 28 2 (2000) 95-103
42. Englund J.A., Walter E.B., Fairchok M.P., Monto A.S., and Neuzil K.M. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115 4 (2005) 1039-1047